Urology
Volume 75, Issue 1 , Pages 20-25 , January 2010

Long-term Outcome of Patients With a Negative Work-up for Asymptomatic Microhematuria

  • Ralph Madeb

      Affiliations

    • Department of Urology, University of Rochester School of Medicine, Rochester, New York
    • ,
  • Dragan Golijanin

      Affiliations

    • Department of Urology, University of Rochester School of Medicine, Rochester, New York
    • ,
  • Joy Knopf

      Affiliations

    • Department of Urology, University of Rochester School of Medicine, Rochester, New York
    • ,
  • Matthew Davis

      Affiliations

    • Department of Urology, University of Rochester School of Medicine, Rochester, New York
    • ,
  • Changyong Feng

      Affiliations

    • Department of Biostatics, University of Rochester School of Medicine, Rochester, New York
    • ,
  • Anne Fender

      Affiliations

    • Department of Urology, University of Rochester School of Medicine, Rochester, New York
    • ,
  • Laura Stephenson

      Affiliations

    • Wisconsin Cancer Reporting System, Bureau of Health Information and Policy, Madison, Wisconsin
    • ,
  • Edward M. Messing

      Affiliations

    • Department of Urology, University of Rochester School of Medicine, Rochester, New York
    • Corresponding Author InformationReprint requests: Edward M. Messing, M.D., F.A.C.S., Department of Urology, Strong Memorial Hospital, 601 Elmwood Ave, Box 656, Rochester, NY 14642

Received 23 March 2009 ,Accepted 13 June 2009.

References 

  1. Cohen RA, Brown RS. Clinical practice (Microscopic hematuria). N Engl J Med. 2003;348:2330–2338
  2. Grossfeld GD, Litwin MS, Wolf JS, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part II: patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology. 2001;57:604–610
  3. Grossfeld GD, Litwin MS, Wolf JS, et al. Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy—part I: definition, detection, prevalence, and etiology. Urology. 2001;57:599–603
  4. Grossfeld GD, Wolf JS, Litwan MS, et al. Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy recommendations. Am Fam Physician. 2001;63:1145–1154
  5. US Preventive Services Task Force. Guide to Clinical Preventive Services. Washington, DC: Office of Disease Prevention and Health Promotion; 1996;
  6. Nabi G, Greene D, O'Donnell MO. Suspicious urinary cytology with negative evaluation for malignancy in the diagnostic investigation of haematuria: how to follow up?. J Clin Pathol. 2004;57:365–368
  7. Messing EM, Vaillancourt A. Hematuria screening for bladder cancer. J Occup Med. 1990;32:838–845
  8. Hiatt RA, Ordonez JD. Dipstick urinalysis screening, asymptomatic microhematuria, and subsequent urological cancers in a population-based sample. Cancer Epidemiol Biomarkers Prev. 1994;3:439–443
  9. Howard RS, Golin AL. Long-term follow up of asymptomatic microhematuria. J Urol. 1991;145:335–336
  10. Khadra MH, Pickard RS, Charlton M, et al. A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol. 2000;163:524–527
  11. Messing EM, Madeb R, Young T, et al. Long-term outcome of hematuria home screening for bladder cancer in men. Cancer. 2006;107:2173–2179
  12. Messing EM, Young TB, Hunt VB, et al. The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J Urol. 1987;137:919–922
  13. Messing EM, Young TB, Hunt VB, et al. Urinary tract cancers found by homescreening with hematuria dipsticks in healthy men over 50 years of age. Cancer. 1989;64:2361–2367
  14. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006;56:106
  15. Johnson E, Daignault S, Zhang Y, et al. Gender disparities in urologic referral of hematuria. J Urol. 2006;175(suppl 4):286
  16. Messing EM. Urothelial tumors of the bladder. In:  Wein AJ,  Kavoussi LR,  Novick AC editor. Campbell-Walsh Urology. Philadelphia, PA: W.B. Saunders; 2007;p. 2407–2445Chapt.75
  17. Lotan Y, Svatek RS, Sagalowsky AI. Should we screen for bladder cancer in a high-risk population? (A cost per life-year saved analysis). Cancer. 2006;107:982–990
  18. Grossman HB, Messing E, Soloway M, et al. Detection of bladder cancer using a point-of-care proteomic assay. JAMA. 2005;293:810–815
  19. Grossman HB, Soloway M, Messing E, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA. 2006;295:299–305
  20. Boman H, Hedelin H, Holmang S, et al. Four bladder tumor markers have a disappointingly low sensitivity for small size and low grade recurrence. J Urol. 2002;167(suppl 4):80–83
  21. Messing EM. Bladder tumor markers. J Urol. 2006;175:1195–1196
  22. Messing EM. Urothelial tumors of the urinary tract. In:  Walsh PC,  Retik AB,  Vaughan ED,  Wein AJ editor. Campbell's-Walsh Urology. Philadelphia, PA: WB Saunders; 2007;
  23. Fisher M. Use and analysis of data—an evaluation of the Wisconsin Cancer Reporting System's completeness of case reporting. Madison, WI: Wisconsin Department of Health and Social Services; 1982;
  24. Evans CP. Evidence-based medicine for the urologist. BJU Int. 2004;94:1–2

 Supported in part by grants from the State of Wisconsin Division of Health and Social Services and from the Ashley Family Foundation.

 Ralph Madeb was supported in part by the Empire State Grant.

PII: S0090-4295(09)02410-8

doi: 10.1016/j.urology.2009.06.107

Urology
Volume 75, Issue 1 , Pages 20-25 , January 2010

Article Tools

* Image Usage & Resolution